OCRF Talks

Q&A with Sarah Adams, M.D., 2011 Liz Tilberis Awardee

Dr. Sarah Adams is a 2011 Liz Tilberis Grant Recipient. Sarah DeFeo: How did you end up becoming a gynecologic oncologist? Sarah Adams: Like many people, I didn’t always know this is what I wanted to do.  After college, I did volunteer work with AmeriCorps.  I was committed to service, and became... 

2011 SGO News: GI Risk Clarified for Bevacizumab

Ovarian cancer patients had a twofold greater risk of gastrointestinal adverse effects when bevacizumab was added to chemotherapy, but the angiogenesis inhibitor did not exacerbate other known risks for GI events, data from a large prospective trial showed. Treatment with bevacizumab was associated... 

2011 SGO News: Genetic Test May Spot Increased Risk for Inherited Ovarian Cancer

Nearly one in four ovarian cancers are inherited, say researchers who are developing a gene-based blood test to identify women with these hereditary cancers. The test, which looks for variations in 22 genes known or suspected to predispose women to ovarian cancer, isn’t ready for prime time yet. But... 

2011 SGO News: Menopause Symptoms Common after Gynecologic Cancer

Most survivors of gynecologic cancers have menopausal symptoms, and at least one in four takes replacement hormones, results of the first study of its kind showed. A survey of 544 gynecologic cancer survivors showed that 80% had one or more menopausal symptoms, investigators reported here at the Society... 

2011 SGO News: Mutation Link to Ovarian Cancer Disputed

  2011 SGO News: Mutation Link to Ovarian Cancer Disputed Developers of a genetic-susceptibility test for ovarian cancer might have jumped the gun, according to an OCRF-funded consortium that found no association between a KRAS mutation and risk of the cancer. Analysis of genetic information... 

2011 SGO News: ESAs Linked to Mortality Risk in Ovarian Cancer

Cancer recurrence and death occurred significantly more often in ovarian cancer patients treated with erythropoietin-stimulating agents (ESAs), data from a retrospective cohort review showed. ESA treatment also was associated with a briefer progression-free survival (PFS) and reduced overall survival,... 

2011 SGO News: PARP Inhibitor Active in Ovarian Cancer

Almost half of patients with heavily pretreated ovarian cancer benefited from an investigational PARP inhibitor, results of a phase I study showed. Of 39 evaluable patients, 10 had partial responses and eight others had stable disease for a minimum of 12 weeks. The two groups combined had a clinical... 

2011 SGO News: MicroRNA May Help Predict Ovarian Cancer Response

Changes in expression of a microRNA showed potential for predicting response to the angiogenesis inhibitor bevacizumab (Avastin) in recurrent serous ovarian cancer, according to results of a small study reported here. Women with low-level expression of miR-378 after bevacizumab and chemotherapy... 

2011 SGO News: Medicare Patients Get Less Than Best Ovarian Cancer Care

Most older patients with ovarian cancer may receive care that doesn’t measure up to national standards, according to an analysis of a National Cancer Institute (NCI) database and Medicare claims data. Ten years of retrospective data from more than 8,000 women found fewer than 40% of advanced... 

Q&A with Gregory Motz, PhD.

Dr. Gregory Motz is a 2011 Ann Schreiber Program of Excellence Grantee. In this interview with OCRF’s Sarah DeFeo, Dr. Motz discusses his research, what motivated him to focus his efforts on ovarian cancer, and what it means to receive a grant from OCRF. Sarah DeFeo:  Tell me about yourself. ...